With the aim of protecting more and more Greek patients, a new product in Cardiovascular Medicine is launched. KERENDIA is now available for patients with CKD & Type 2 Diabetes. Welcome to Bayer Hellas internal Kerendia launch event, focusing on educating & preparing the Sales Team for a successful product promotion in the Greek market. In this event, you familiarized yourselves with the promotional materials & the role plays. This is the first POAP related to a pharmaceutical product. If you received this POAP, you are a True Pioneer in the Web3 space. Bayer is proudly promoting innovative practices. https://www.bayer.com/en/poap-tc

I work in DSSS and a Subject Matter Expert in Rave and Integrations

I am a "Senior Insight Solutions Lead" which means that I work in DAIS team and try to generate novel insights for our R&D (and beyond) organization

You have been part of our Bayer R&D Buffet in November, where we have focused on every aspect of our TNN implementation. The food for thought was delicious, the outlook was bright, and our journey together as ONE R&D looks promising! Thank you for being part of our team that helps pathing the way for an inclusive and innovative workspace. Website: https://www.bayer.com/

You have been part of our Bayer R&D Buffet in November, where we have focused on every aspect of our TNN implementation. The food for thought was delicious, the outlook was bright, and our journey together as ONE R&D looks promising! Thank you for being part of our team that helps pathing the way for an inclusive and innovative workspace. Website: https://www.bayer.com/

Nikola Milosevic is a senior computational scientist at Bayer Pharma R&D, Data Sciences and AI, Data Assets and Insights Solutions team. He is passionate about natural language processing, and therefore a creator of Linguist platform, project owner of NLP@Scale project and involved in HubbleSearch project. He also works on relationship extraction from text for knowledge graphs, and large language models (e.g. Fact Finder). Nikola has a PhD from the University of Manchester (CASE project with AstraZeneca), and previous degrees from University of Belgrade. He has experience with few SAAS startups and smaller companies before joining Bayer in January 2020